Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 41, Issue 3, 1998, Pages 491-500

  Zelefsky, Michael J ^a   Leibel, Steven A ^a   Gaudin, Paul B ^a   Kutcher, Gerald J ^a   Fleshner, Neil E ^b   Venkatramen, E S ^a   Reuter, Victor E ^a   Fair, William R ^b   Ling, C Clifton ^a   Fuks, Zvi ^a  

^a Dept Surg Mem Sloan Kettering C ^*  (United States)

^b Urology Service   (United States)

Author keywords

Biopsy; Conformal radiotherapy; Dose escalation; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, COMPUTER-ASSISTED; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 0031779250     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00091-1     Document Type: Article

References (76)

1. Ackerman D.A., Barry J.M., Wicklund R.A., Olson N., Lowe B.A. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J. Urol. 150:1993;1845-1850.
2. Bigg S.W., Kavoussi L.R., Catalona W.J. Role of nerve-sparing radical prostatectomy for clinical stage B2 prostate cancer. J. Urol. 144:1990;1420-1424.
3. D'Amico A.V., Whittington S., Malkowicz B., Schall M., Tomaszewski J., Schultz D., Kao G., anArsdalen K., Wein A. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol. 154:1995;131-138.
4. Epstein J.I., Partin A.W., Sauvageot J., Walsh P.C. Prediction of progression following radical prostatectomy A multivariate analysis of 721 men with long-term follow-up . Am. J. Surg. Pathol. 20:1996;286-295.
5. Epstein J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression following radical retropubic prostatectomy. Cancer. 71:1993;3582-3593.
6. Huland H., Hammerer P., Henke R.P., Huland E. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination, PSA, and the results of six systematic biopsies. J. Urol. 155:1996;1344-1347.
7. Jones E.C. Resection margin status in radical retropubic prostatectomy specimens Relationship to type of operation, tumor size, tumor grade and local tumor extension . J. Urol. 144:1990;89-96.
8. Ohori M., Wheeler T.M., Kattan M.W., Goto Y., Scardino P.T. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol. 154:1995;1818-1824.
9. Paulson D.F. Impact of radical prostatectomy in the management of clinically localized disease. J. Urol. 152:1994;1826-1830.
10. Rosen M.A., Goldstone L., Lapin S., Wheeler T., Scardino P.T. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J. Urol. 148:1992;331-337.
11. Stamey T.A., Villers A.A., McNeal J.E., Link P.C., Freiha F.S. Positive surgical margins at radical prostatectomy Importance of the apical dissection . J. Urol. 143:1990;1166-1172.
12. Van Den Ouden D., Bentvelsen F.M., Boeve E.R., Schroder F.H. Positive margins after radical prostatectomy Correlation with local recurrence and distant progression . Br. J. Urol. 72:1993;489-494.
13. Weldon V.E., Tavel F.R., Neuwirth H., Cohen R. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J. Urol. 153:1995;1565-1569.
14. Abi-aad A.S., MacFarlane M.T., Stein A., Dekernion J.B. Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J. Urol. 47:1991;952-955.
15. Anscher M.S., Prosnitz L.R. Multivariate analysis of factors predicting local relapse after radical prostatectomy - possible indications for postoperative irradiation. Int. J. Radiat. Oncol. Biol. Phys. 24:1991;941-947.
16. Blute M.L., Nativ O., Zincke H., Farrow G.M., Therneau T., Lieber M.M. Pattern of failure after radical prostatectomy for clinically localized adenocarcinoma of the prostate Influence of tumor deoxyribonucleic acid ploidy . J. Urol. 142:1989;1262-1265.
17. Middleton R.G., Smith R.G., Smith J.A. Jr, Melzer R.B. Patient survival and local recurrence rate following radical prostatectomy for prostatic carcinoma. J. Urol. 135:1986;422-424.
18. Schellhammer P.F. Radical prostatectomy Patterns of local failure and survival in 67 patients . J. Urol. 31:(3):1988;191-197.
19. Walsh P.C., Jewett H.J. Radical surgery for prostatic cancer. Cancer. 45:1980;1906-1911.
20. Zietman A.L., Shipley W.U., Willett C.G. Residual disease after radical surgery or radiation therapy for prostate cancer Clinical significance and therapeutic implications . Cancer. 71:1993;959-969.
21. Cox J.D., Stoffel T.J. The significance of needle biopsy after irradiation for stage C adenocarcinoma of the prostate. Cancer. 40:1977;156-160.
22. Crook J.M., Perry G.A., Robertson S., Esche B.A. Routine prostate biopsies following radiotherapy for prostate cancer Results for 226 patients . Urology. 45:1995;624-632.
23. Hill D.R., Crews L.E., Walsh P.C. Prostate carcinoma Radiation treatment of the primary and regional lymphatics . Cancer. 34:1974;156-160.
24. Kagan A.R., Gordon J., Cooper J.F., Gilbert H., Nussbaum H., Chan P. A clinical appraisal of post-irradiation biopsy in prostatic cancer. Cancer. 39:1977;637-641.
25. Kiesling V.J., McAninch J.W., Goebel J.L., Agee R.E. External beam radiotherapy for adenocarcinoma of the prostate A clinical followup . J. Urol. 124:1980;851-854.
26. Laverdiere J., Gomez J.L., Cusan L., Suburu E.R., Diamond P., Lemoy M., Candas B., Fortin A., Labrie F. Beneficial effect of combination hormonal therapy administered prior to and following external beam radiation therapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;247-252.
27. Nachtsheim D.A., McAninch J.W., Stutzman R.E., Goebel J.L. Latent residual tumor following external radiotherapy for prostate adenocarcinoma. J. Urol. 120:1978;312-314.
28. Perez C.A., Bauer W., Garza R., Royce R.K. Radiation therapy in the definitive treatment of localized carcinoma of the prostate. Cancer. 40:1977;1425-1433.
29. Rhamy R.K., Wilson S.K., Caldwell W.L. Biopsy-proved tumor following definitive irradiation for resectable carcinoma of the prostate. J. Urol. 107:1972;627-630.
30. Scardino P.T., Frankel J.M., Wheeler T.M., Meacham R.B., Hoffman G.S., Seale C., Wilbanks J.H., Easley J., Carlton C.E. The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J. Urol. 135:1986;510-515.
31. Sewell R.A., Braren V., Wilson S.K. Extended biopsy follow-up after full course radiation for resectable prostatic carcinoma. J. Urol. 113:1975;371-373.
32. Fuks Z., Leibel S.A., Wallner K.E., Begg C.B., Fair W.R., Anderson L.L., Hilaris B.S., Whitmore W.F. The effect of local control on metastatic dissemination in carcinoma of the prostate Long-term results in patients treated with 125-I implantation . Int. J. Radiat. Oncol. Biol. Phys. 21:1991;537-547.
33. Kuban D.A., El-Mahdi A.M., Schellhammer P.F. Potential benefit of improved local tumor control in patient with prostate carcinoma. Cancer. 75:1995;2373-2382.
34. Lai P.P., Perez C.A., Lockett M.A. Prognostic significance of pelvic recurrence and distant metastasis in prostate carcinoma following definitive radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 24:1992;423-430.
35. Zagars G.K., von Eschenbach A.C., Ayala A.G., Schultheiss T.E., Sherman N.E. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer. 68:1991;2370-2377.
36. Yorke E.D., Fuks Z., Norton L., Whitmore W., Ling C.C. Modeling the development of metastases from primary and locally recurrent tumors Comparison with a clinical data base for prostatic cancer . Cancer Res. 53:1993;2987-2993.
37. Ten Haken R.K., Perez-Tamayo C., Tesser R.J., McShan D.L., Frass B.A., Lichter A. Boost treatment of the prostate using shaped fixed fields. Int. J. Radiat. Oncol. Biol. Phys. 6:1989;193-200.
38. Zelefsky M.J., Leibel S.A., Fuks Z. Conventional external beam radiation therapy for prostate cancer Where do we go from here? Int. J. Radiat. Oncol. Biol. Phys. 26:1993;365-367.
39. Leibel S.A., Zelefsky M.J., Kutcher G.J., Burman C.M., Mohan R., Mageras G.S., Ling C.C., Fuks Z. The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin. Oncol. 21:1994;580-597.
40. Thames H.D., Schultheiss T.E., Hendry J.H., Tucker S.L., Dubray B.M., Brock W.A. Can modest escalations of dose be detected as increased tumor control. Int. J. Radiat. Oncol. Biol. Phys. 22:1994;241-246.
41. Zagars G.K., Schultheiss T.E., Peters L.P. Inter-tumor heterogeneity and radiation dose control curves. Radiother. Oncol. 8:1987;353-362.
42. Lawton C.A., Won M., Pilepich M.V., Asbell S.O., Shipley W.U., Hanks G.E., Cox J.D., Perez C.A., Sause W.T., Doggett S.R.L., Rubin P. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate Analysis of RTOG studies 7506 and 7706 . Int. J. Radiat. Oncol. Biol. Phys. 21:1991;935-939.
43. Leibel S.A., Zelefsky M.J., Kutcher G.J., Burman C.M., Kelson S., Fuks Z. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate Interim report of a phase I dose-escalation study . J. Urol. 152:1994;1792-1798.
44. Prostate. Beahrs O.H., Henson D.E., Hutter R.V.P., Kennedy B.J. Manual for staging of cancer. 4th ed. 1992;181-183 J.B. Lippincott, Philadelphia.
45. Gleason D.F. Histologic grading and clinical staging of prostatic carcinoma. Tannenbaum M. Urologic pathology The prostate . 1977;171-197 Lea & Febiger, Philadelphia.
46. Zelefsky M.J., Happersett L., Leibel S.A., Burman C.M., Schwartz L., Dicker A.P., Kutcher G.J., Fuks Z. The effect of treatment positioning on normal tissue dose in patients with prostate cancer treated with three-dimensional conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;13-19.
47. Zelefsky M.J., Leibel S.A., Burman C.M., Kutcher G.J., Harrison A., Happersett L., Fuks Z. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 29:1994;755-761.
48. Zelefsky M.J., Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer Reducing the potential morbidity of therapy . Urol. 49:1997;38-45.
49. Kavadi V.S., Zagars G.K., Pollack A. Serum prostate specific antigen after radiation therapy for clinically localized prostate cancer Prognostic implications . Int. J. Radiat. Oncol. Biol. Phys. 30:1994;279-287.
50. Zelefsky M.J., Leibel S.A., Wallner K.E., Whitmore W.F. Jr, Fuks Z. The significance of normal serum PSA in the follow-up after definitive radiation therapy for prostatic cancer. J. Clin. Oncol. 13:1995;459-463.
51. Consensus statement Guidelines for PSA following radiation therapy . Int. J. Radiat. Oncol. Biol. Phys. 37:1997;1035-1041.
52. Crook J.M., Bahdur Y.A., Robertson S.J., Perry G.A., Esche B.A. Evaluation of radiation effect, tumor differentiation and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer. 79:1997;81-89.
53. Kaplan E.L., Meier P. Nonparametic estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-816.
54. Mantel N. Evaluation of survival data and two rank order statistics arising in its consideration. Cancer Chemo. Reports. 50:1966;163-170.
55. Mantel N., Byar D.P. Evaluation of response-time data involving transient states An illustration using heart transplant data . J. Am. Stat. Assoc. 69:1974;81-86.
56. Cox D.R. Regression models and life tables. J. Roy. Statist. Soc. 34:(Series B):1972;187-220.
57. Andersen P.K., Gill R.D. Cox's regression model for counting processes A large sample study . Ann. Stat. 10:1982;1100-1120.
58. Critz F.A., Tarlton R.S., Holliday D.A. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer-I-125 implant followed by external beam radiation. Cancer. 75:1995;2383-2391.
59. Zelefsky M.J., Leibel S.A., Kutcher G.J., Kelson S., Ling C.C., Fuks Z. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. Cancer J. Sci. Am. 1:1995;42-50.
60. Prestidge B.R., Hoak D.C., Grimm P.D., Ragde H., Cavanagh W., Blasko J.C. Posttreatment biopsy results following interstitial brachytherapy in early stage prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;31-39.
61. Pilepich M.V., Krall J., George F.W. Treatment-related morbidity in phase III RTOG studies of extended-field irradiation for carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 10:1984;1861-1867.
62. Hendry J.H., Moore J.V. Is the steepness of dose-incidence curves for tumour control or complications due to variation before or as a result of irradiation? Brit. J. Rad. 57:1984;1045-1046.
63. Munro T.R., Gilbert C.W. The relation between tumour lethal doses and the radiosensitivity of tumour cells. Brit. J. Rad. 34:1961;246-250.
64. Porter E.H. The statistical dose-cure relationships for irradiated tumors. Brit. J. Radiol. 53:1980;336-345.
65. Stamey T.A., Ferrari M.K., Schmid H. The value of serial prostate specific antigen determinations 5 years after radiotherapy Steeply increasing values characterize 80% of patients . J. Urol. 150:1993;1856-1859.
66. D'amico A.V., Whittington R., Kaplan I., Beard C., Jiroutek M., Malkowicz B., Wein A., Coleman C.N. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of 4 >20 ng/ml. Int. J. Radiat. Oncol. Biol. Phys. 37:1997;1053-1058.
67. Fukunaga-Johnson N., Sandler H.M., McLaughlin P.W., Strawderman M.S., Grualva K.H., Kish K.E., Lichter A.S. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;311-317.
68. Hanks G.E., Schultheiss T.E., Hanlon H.A., Hunt M., Lee W.R., Epstein B.E., Coia L.R. Optimization of conformal radiation treatment of prostate cancer Report of a dose escalation study . Int. J. Radiat. Oncol. Biol. Phys. 37:1997;543-555.
69. Kupelian P., Katcher J., Levin H., Zippe C., Suh J., Macklis R., Klein E. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores . Cancer J. Sci. Am. 3:1997;78-87.
70. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Tomaszewski J.E., Wein A. Prostate-specific antigen failure despite pathologically organ confined and margin negative prostate cancer The basis for an adjuvant therapy trial . J. Clin. Oncol. 15:1997;1465-1469.
71. Partin A.W., Pound C.R., Clemens J.Q., Epstein J.I., Walsh P.C. Serum PSA after anatomic radical prostatectomy The Johns Hopkins experience after 10 years . Urol. Clin. North Am. 20:1993;713-725.
72. Bentzen S.M. Radiobiological considerations in the design of clinical trials. Radiother. Oncol. 32:1994;1-11.
73. Dutreix J., Tubiana M., Dutreix A. An approach to the interpretation of clinical data on tumour control probability-dose relationship. Radiother. Oncol. 11:1988;239-258.
74. Shipley W.U., Verhey L.J., Munzenrider J.E., Suit H.D., Urie M.M., McManus P.L., Young R.H., Shipley J.W., Zeitman A.L., Biggs P.J., Heney N.M., Goitein M. Advanced prostate cancer The results of a randomized comparative trial of high dose irradiation boosting with conformal prostons compared with conventional dose irradiation using photons alone . Int. J. Radiat. Oncol. Biol. Phys. 32:1995;3-12.
75. Hanks G.E., Lee W.R., Hanlon A.L., Hunt M., Kaplan E., Epstein B.E., Morsas B., Schultheiss T.E. Conformal technique dose escalation for prostate cancer Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen >10 ng/ml . Int. J. Radiat. Oncol. Biol. Phys. 35:1996;862-868.
76. Ling C.C., Burman C., Chui C.S., Kutcher G.J., Leibel S.A., LoSasso T., Mohan R., Bortfeld T., Reinstein L., Spirous S., Wang X.H., Wu Q., Zelefsky M.J., Fuks Z. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with multileaf collimation. Int. J. Radiat. Oncol. Biol. Phys. 35:1996;721-730.